



The Critical Role of Advanced Practice Providers

in Optimizing Care for Patients With Multiple Myeloma

Multiple myeloma (MM) is a rare, incurable cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.^{1,2,3}

Approximately **36,000** new patients are diagnosed with multiple myeloma and almost **13,000** people die from the disease each year.²

For most multiple myeloma patients, the length of remission decreases with each new relapse, and depth and duration of response to treatment is longer in the first line of therapy, **making early diagnosis and first-line treatment decisions critical to prognosis.**⁴



Who are Advanced Practice Providers and what is their role on the care team?

Advanced Practice Providers (APPs) are a category of health care practitioners with advanced degrees, such as nurse practitioners and physician assistants.

APPs work closely with the entire care team, including the oncologist to:




Provide surveillance and management of disease symptoms




Help patients understand and navigate their treatment journeys

The following research was commissioned by Janssen Oncology and the Advanced Practitioner Society for Hematology and Oncology (APSHO) through The Harris Poll among 200 APPs (131 nurse practitioners and 69 physician assistants) who see patients with multiple myeloma and 100 multiple myeloma patients in the United States.


The relationship between a multiple myeloma patient and their APP is central to how they experience their multiple myeloma treatment journey.



of multiple myeloma patients have **never heard the term *Advanced Practice Provider (APP)*** despite the value they bring to their care.⁵



of patients with an APP agree **that APPs are essential** to their multiple myeloma care.⁵




of patients **feel like they could ask APPs questions** they could not ask a doctor/oncologist.⁵




APPs want to be more involved with patient care, both at diagnosis and throughout duration of therapy, but are faced with challenges.

Diagnosis represents a pivotal moment to build a strong relationship between a patient and their care team.

Leading factors APPs feel prevent them from being more involved when their patients are first diagnosed with multiple myeloma include:



of APPs feel being more involved in a patient's disease management at the time of diagnosis would help them better manage the patient's overall treatment journey to provide the best care possible.⁵



48% of APPs face time constraints during the appointment.⁵




38% of APPs feel the patients would prefer the oncologist to be more involved.⁵



35% of APPs state the oncologist typically leads the appointment with patients.⁵

APPs desire more education and resources specific to multiple myeloma.



In response to these data, Janssen Oncology, in partnership with the Advanced Practitioner Society for Hematology and Oncology (APSHO), launched **Make It HAPPen™**, a national campaign that is raising awareness of APPs as critical stakeholders in optimizing care for people living with multiple myeloma.

*Small base (<100) results to be interpreted with caution.

1. Cancer Stats: Myeloma. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Accessed August 17, 2023. <https://seer.cancer.gov/statfacts/html/mulmy.html>
2. Learn More About Multiple Myeloma. The Multiple Myeloma Research Foundation. Accessed August 17, 2023.
3. What is Multiple Myeloma? The Multiple Myeloma Research Foundation. Accessed August 17, 2023. <https://themmrf.org/multiple-myeloma/>
4. Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. *BMC Cancer*. 2020;20(1). doi:10.1186/s12885-020-07503-y
5. Janssen Oncology & The Advanced Practitioner Society for Hematology & Oncology. About the Survey: This survey was conducted online within the United States by The Harris Poll on behalf of Janssen Oncology & APSHO, from May 15-June 9, 2023, among 100 US adults ages 18 and older who have been diagnosed with multiple myeloma and 200 APPs (nurse practitioners [NPs] [n=131] and physicians assistants [PAs] [n=69]) who see at least 3 patients with multiple myeloma annually.

